Sacituzumab Govitecan (Trodelvy) in Metastatic Triple-Negative Breast Cancer
Evidence Based Medicine presented by InpharmD™ · InpharmD™
June 18, 20218m 13s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A global, phase-3 trial conducted to evaluate the efficacy and safety of sacituzumab govitecan (Trodelvy) as compared with single-agent chemotherapy of the physician's choice in patients with relapsed or refractory metastatic triple-negative breast cancer. This trial led to the FDA's accelerated approval of Trodelvy for this indication.